MaxCyte, Inc. (NASDAQ:MXCT) Receives Consensus Rating of “Hold” from Analysts

MaxCyte, Inc. (NASDAQ:MXCT) has earned an average recommendation of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $7.00.

Several equities research analysts recently issued reports on the company. BTIG Research reissued a “neutral” rating on shares of MaxCyte in a research report on Monday, August 11th. William Blair lowered shares of MaxCyte from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 7th. Wall Street Zen raised shares of MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a report on Monday.

Hedge Funds Weigh In On MaxCyte

Several institutional investors have recently made changes to their positions in MXCT. Farther Finance Advisors LLC lifted its holdings in shares of MaxCyte by 7,935.4% in the 2nd quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company’s stock worth $26,000 after purchasing an additional 11,665 shares during the last quarter. Prudential Financial Inc. bought a new position in MaxCyte during the 2nd quarter worth $26,000. CWM LLC increased its position in MaxCyte by 92.7% in the second quarter. CWM LLC now owns 12,132 shares of the company’s stock worth $26,000 after buying an additional 5,836 shares during the period. May Hill Capital LLC acquired a new stake in MaxCyte in the second quarter worth $27,000. Finally, State of Wyoming bought a new stake in MaxCyte in the second quarter valued at $38,000. 68.81% of the stock is owned by institutional investors.

MaxCyte Stock Performance

NASDAQ:MXCT opened at $1.67 on Friday. The company has a market capitalization of $178.15 million, a price-to-earnings ratio of -3.88 and a beta of 1.23. MaxCyte has a one year low of $1.26 and a one year high of $5.20. The stock has a 50-day simple moving average of $1.60 and a 200 day simple moving average of $1.85.

MaxCyte (NASDAQ:MXCT) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The firm had revenue of $6.41 million for the quarter, compared to analyst estimates of $8.37 million. MaxCyte had a negative net margin of 125.22% and a negative return on equity of 22.12%. On average, equities research analysts forecast that MaxCyte will post -0.42 EPS for the current fiscal year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.